Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock, assigning it an Overweight rating and setting a price target of $200.
What Happened: Cidara announced it will be presenting at the European Scientific Working Group on Influenza’s 10th Conference taking place October 20-23 in Valencia, Spain. The presentation, scheduled for October 23, will cover translational efficacy data of CD388 in mouse influenza infection models and its application to prevention efficacy in the recently completed Phase 2b NAVIGATE clinical study.
